Novel Targeted Therapy Trial for Patients with Small Cell Lung Cancer
1-800-641-2422
Targeted therapy with CDK4/6 inhibitors in chemo-refractory/relapsed, Rb wild-type extensive Small cell lung cancer (SCLC), large cell neuroendocrine lung cancer, extrapulmonary small cell cancers and other high grade neuroendocrine cancers of the lung, an open label phase 2 trial.
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Cancer - Lung
Study Purpose
University Hospitals is offering a new treatment for patients with small cell lung cancer (SCLC) that have not responded to treatment (refractory) or have relapsed after chemotherapy treatment. Some cancer cells are resistant to treatment because they have pathways and systems that allow the cancer cells to continue to divide and grow. A subgroup of SCLC has high levels of two proteins that push the cancer cell into growth mode. These proteins act like accelerators in a car. These two proteins called CDK4 and CDK6 can be turned off by using a specific drug that targets their activity. This study will test how well the investigational drug, Abemaciclib, works by selectively turning off the overactive CDK4 and CDK6 and helps to shrink the lung cancer tumors in the body.
Who Can Participate
AGE: 19 years and older
Locations
UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: STUDY20191045
- StudyID: CASE1519
- ClinicalTrials.gov: NCT04010357
1-800-641-2422
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422